A proton-pump inhibitor (PPI) is recommended for patients with a high risk of gastrointestinal bleeding induced by nonsteroidal anti-inflammatory drugs (NSAIDs). PPIs utilize CYP2C19, a liver enzyme of cytochrome P450, for their inactivation, and this same enzyme mediates the generation of the active substance from the prodrug, clopidogrel, a platelet ADP-receptor blocker. Therefore, concerns have been raised that concomitant use of PPIs and clopidogrel may weaken clopidogrel’s efficacy through competitive inhibition of CYP2C19 (Figure) and/or worsen the clinical outcome.

Figure. Possible competitive inhibition between clopidogrel and proton-pump inhibitors (PPIs). Clopidogrel is a prodrug that utilizes CYP2C19 for its activation, whereas PPIs utilize CYP2C19 for their inactivation. Therefore, concerns have been raised as to whether or not competitive inhibition occurs that may weaken the antiplatelet function of clopidogrel on concomitant PPI use.

In this issue of the Journal, Yano et al present their results from a randomized, open-labeled prospective study in which they found that omeprazole, a PPI, did not affect the antiplatelet function of clopidogrel or the occurrence of clinical events in patients undergoing coronary stent implantation for acute coronary syndrome (ACS) as compared with an H2 blocker. Theirs is the first prospective study in Japanese patients with regard to this subject and provides important findings for clinical settings in Japan.

Today, more than 250,000 people per year are treated with coronary stent implantation in Japan. The most severe and notable complication is stent thrombosis and dual antiplatelet therapy (DAPT) with aspirin and an ADP-receptor blocker is routinely administered for its prevention. However, the inter-individual variability of the antiplatelet effects of clopidogrel is very high and is dependent on its pharmacological properties. Clopidogrel is a prodrug that is changed into a bioactive substance through a metabolic activation process mediated by cytochrome p450 enzymes (CYPs). Among the CYPs, CYP2C19 has been reported to contribute most strongly to the activation of clopidogrel. The CYP2C19 gene is well known for harboring loss-of-function single nucleotide polymorphisms (SNPs) called CYP2C19*2 and CYP2C19*3. The patients with CYP2C19 SNP(s) exhibit an attenuated antiplatelet function of clopidogrel. Moreover, the CYP2C19 SNPs are associated with an increase in stent thrombosis. Notably, the prevalence of carriers with the SNPs in both alleles, who are referred to as poor metabolizers, is 3–5% in Caucasians and ≈20% in Asian populations. Therefore, SNPs of CYP2C19 might be a more serious problem in the clinical settings of Asian countries.

A well-known adverse effect of aspirin is gastrointestinal bleeding. In 2008, the ACCF/ACG/AHA expert consensus document for prevention of gastrointestinal bleeding under NSAID therapy was published, in which it was described that PPIs are recommended for high-risk bleeding patients such as those undergoing DAPT. On the other hand, it is also known that the degradation/inactivation of PPIs more or less utilizes CYP2C19. Therefore, competitive inhibition might occur when there is concomitant use of PPI and clopidogrel. Based on clinical and experimental results, ACCF/ACG/AHA revised the expert consensus in 2010 to include the consistent inhibition of clopidogrel efficacy by omeprazole, but as yet unknown effects of other PPIs because of the lack of sufficient data. The degree of contribution by CYP2C19 in the inactivation of each PPI is variable. Previous data suggest that the contribution of CYP2C19 is higher for omeprazole than for lansoprazole, rabeprazole and esomeprazole.

With regard to the Japanese population, a few studies have so far been published on the pharmacological effects of concomitant use of PPIs on clopidogrel efficacy. Furuta et al conducted a crossover study with 39 healthy volunteers in which the antiplatelet effects were evaluated by the optical aggregom
eter. They demonstrated that omeprazole and rabeprazole, but not lansoprazole, slightly but significantly attenuated the antiplatelet function of clopidogrel in those without CYP2C19 SNPs, and the effects of PPIs were not detected in those with CYP2C19 SNP(s). My group also conducted a crossover study to analyze the effects of concomitant use of omeprazole or rabeprazole in 25 patients during DAPT, in which platelet reactivity was measured with the VerifyNow system. We reported that patients taking omeprazole exhibited slightly higher platelet reactivity than those taking rabeprazole, and that the reactivity under rabeprazole intake was similar to that detected in control patients not taking PPI. Thus, these studies suggest that omeprazole might significantly, although slightly, decrease the antiplatelet function of clopidogrel in the Japanese population.

In this issue of the Journal, however, Yano et al demonstrate that platelet reactivity, as evaluated by the phosphorylation levels of vasodilator-stimulated phosphoprotein (VASP), under DAPT with concomitant use of omeprazole at 14–28 days after admission for ACS was similar to that with concomitant use of famotidine, an H2 blocker. Theoretically, famotidine is not metabolized by CYP2C19, and our study also demonstrated that the addition of famotidine did not affect the antiplatelet effect of clopidogrel. Therefore, these findings strongly suggest that omeprazole does not affect clopidogrel efficacy. The larger number of patients analyzed in this study (n=138) would support the reliability of their results more strongly than the 2 aforementioned studies. However, the time points for evaluation of platelet reactivity were between 2 and 4 weeks after stent implantation in ACS patients, a time when platelet reactivity is elevated. The effects of ACS on platelet reactivity might have masked the effects of the drugs. If PPIs affect the antiplatelet function of clopidogrel, they may adversely affect the prognosis of patients after stent implantation. The prospective randomized Cogent Study that was conducted in the USA recently showed that omeprazole reduced gastrointestinal events without increasing cardiovascular events. Furthermore, the TIMI38/TIMI44 trials demonstrated that concomitant use of omeprazole did not increase cardiovascular events, although it increased the number of patients classified as having ‘clopidogrel resistance’. Thus, omeprazole does not seem to increase cardiovascular events in patients under DAPT in Western countries. The study by Yano et al reports results from a study that is, as far as I know, the first prospective randomized study for Japanese patients regarding this issue. During a follow-up period of 12 months, adverse cardiovascular events, including death from cardiovascular causes, spontaneous myocardial infarction, unstable angina, stent thrombosis, target vessel revascularization, non-target lesion revascularization, and ischemic stroke, occurred in 13% of patients in the omeprazole group and 17% in the famotidine group. The incidences were not statistically different. It could be because the number of patients enrolled in the study was small; 138 patients were divided into the omeprazole and famotidine groups. The hard endpoints of death from cardiovascular causes, myocardial infarction or stent thrombosis did not occur in the study. Therefore, it seems somewhat premature to conclude from this study alone that PPIs have no influence on cardiovascular endpoints. However, 2 observational studies have recently been performed in Japan, and both also showed that cardiovascular events in patients under clopidogrel intake occurred similarly with or without PPI intake. Collectively, concomitant use of PPIs with clopidogrel does not seem to increase cardiovascular risk in the Japanese population.

In summary, the report by Yano et al in this issue of the Journal suggests that concomitant use of omeprazole with clopidogrel does not affect the antiplatelet function of clopidogrel and that omeprazole had no effect on clinical outcomes during 12 months following stent implantation in ACS patients. Their data must provide important information for the clinical setting, especially in Japan.

**Disclosures**

Conflict of Interest: None.

**References**


Circulation Journal Vol.76, November 2012